论文部分内容阅读
目的研讨急性脑梗死(CI)伴糖尿病(DM)患者运用丁苯肽治疗的临床价值。方法从我院2015年2月-2016年2月选取60例CI伴DM患者参与研究试验,并随机划分为两组(30例/组),Ⅰ组接受常规对症治疗,Ⅱ组在上述治疗下接受丁苯肽用药,评估及分析两组的治疗效果。结果两组治疗后的空腹血糖值相比(P>0.05),统计学不成立。治疗前,两组接受NIHSS量表、Bl指数评测,数据相比(P>0.05),统计学不成立;治疗后,Ⅱ组上述两项数据值相比Ⅰ组均显著改善,数据满足(P<0.05),统计学成立。两组试验治疗期间均未产生严重不良反应。结论丁苯肽对促进CI伴DM患者的神经功能恢复、提高患者生活能力均有显著效果,且安全可靠,值得推荐。
Objective To study the clinical value of the treatment of butanil in patients with acute cerebral infarction (CI) and diabetes mellitus (DM). Methods From February 2015 to February 2016 in our hospital, 60 patients with CI-DM were enrolled in the study and randomly divided into two groups (30 cases / group), group Ⅰ received routine symptomatic treatment, group Ⅱ under the above treatment To receive butanil treatment, assessment and analysis of the two groups of treatment. Results After treatment, the fasting blood glucose values of the two groups were compared (P> 0.05), and the statistics did not hold. Before treatment, the two groups received NIHSS scale, Bl index evaluation, the data compared (P> 0.05), the statistics did not hold; after treatment, the two data in group Ⅱ were significantly improved compared with the group Ⅰ, the data meet (P < 0.05), statistics established. No serious side effects occurred during the two experimental treatments. Conclusion Butyl peptidyl can promote the recovery of neurological function and improve the life ability of patients with CI with DM, and it is safe and reliable, which is worth recommending.